$2,975.90 general Payment -- Regeneron Pharmaceuticals to Dr. Karen Harris
Regeneron Pharmaceuticals payment to Ophthalmology doctor for Wegovy education
This page provides a detailed analysis of a $2,975.90 general payment from Regeneron Pharmaceuticals to Dr. Karen Harris. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $2,975.90 |
| Payment Type | general |
| Payment Nature | Education |
| Pharmaceutical Company | Regeneron Pharmaceuticals |
| Physician | Dr. Karen Harris |
| NPI Number | 1063479894 |
| Physician Specialty | Ophthalmology |
| Location | City, MN |
| Date of Payment | 2025-12-13 |
| Related Drug/Device | Wegovy |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Regeneron Pharmaceuticals made a $3.0K general payment to Karen Harris, a Ophthalmology specialist in City, MN. The payment was associated with Wegovy. The payment of $2,975.90 to Dr. Karen Harris for "Education" by Regeneron Pharmaceuticals is noted. The payment is associated with Wegovy, a drug primarily used for weight management. This payment occurred on December 13, 2025, in City, MN.
Patient Guidance: What This Payment Means for You
This payment was for educational purposes related to a medication; consult your doctor to understand if this medication is appropriate for your health needs. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments for educational purposes to ophthalmologists are less common than for specialties directly involved in prescribing weight-management drugs, but not unusual if the education is relevant to broader patient health.
Regulatory Context: Sunshine Act Requirements
Payments to physicians by manufacturers must be reported under the Sunshine Act to ensure transparency in the healthcare industry.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- physician-payments
- drug-education
- regeneron-pharmaceuticals
- wegovy
- ophthalmology
Understanding general Payments
general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.
Frequently Asked Questions About This Payment
What was this $3.0K payment for?
This was a general payment of $3.0K from Regeneron Pharmaceuticals to Karen Harris, categorized as "Education". It was associated with Wegovy. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Karen Harris accept pharmaceutical money?
Yes, Karen Harris received this $3.0K payment from Regeneron Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Karen Harris's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this general payment?
A general payment of $3.0K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Ophthalmology?
To compare this payment against Ophthalmology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Ophthalmology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Karen Harris's relationship with Regeneron Pharmaceuticals?
The payment nature is categorized as "Education", suggesting a focus on professional development or information dissemination. This $3.0K general payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Ophthalmology?
The specific drug mentioned, Wegovy, is a GLP-1 receptor agonist, often prescribed for obesity.
What should patients do after learning about this payment?
This payment was for educational purposes related to a medication; consult your doctor to understand if this medication is appropriate for your health needs.
What else should I know about this general payment?
Dr. Harris's specialty is Ophthalmology, which may not be the primary specialty for prescribing Wegovy.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.